{"id":48121,"date":"2022-09-08T17:02:15","date_gmt":"2022-09-08T15:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pharmacogenomics-market-report-2022-increased-collaborations-and-product-approvals-to-drive-growth-researchandmarkets-com\/"},"modified":"2022-09-08T17:02:15","modified_gmt":"2022-09-08T15:02:15","slug":"pharmacogenomics-market-report-2022-increased-collaborations-and-product-approvals-to-drive-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pharmacogenomics-market-report-2022-increased-collaborations-and-product-approvals-to-drive-growth-researchandmarkets-com\/","title":{"rendered":"Pharmacogenomics Market Report 2022: Increased Collaborations and Product Approvals to Drive Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Pharmacogenomics Market, by Technology, by Application, by End User, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nPharmacogenomics is a branch of pharmacology that studies the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with drug efficacy or toxicity. It seeks to develop rational methods for optimizing drug therapy in relation to the patient’s genotype, in order to achieve maximum efficacy with minimal side effects.\n<\/p>\n

\nSuch approaches promise the advent of personalized medicine, in which drugs and drug combinations are optimized for each individual’s unique genetic makeup. Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.\n<\/p>\n

\nMarket Dynamics<\/strong>\n<\/p>\n

\nKey players operating in the global pharmacogenomics market are focusing on adoption of growth strategies such as collaborations and product approvals, which are expected to drive the market growth during the forecast period.\n<\/p>\n

\nFor instance, in February 2019, the University of Arizona College of Medicine-Phoenix and Banner Health collaborated to prevent life-threatening adverse reactions to medications. The Flinn Foundation is a privately endowed, philanthropic grant-making organization, awarded the Division of Clinical Data Analytics and Decision Support (CDADS) at the University of Arizona College of Medicine – Phoenix US$ 1.5 million to incorporate pharmacogenomics and clinical decision support into clinician training and medical practice.\n<\/p>\n

\nMoreover, in December 2021, Thermo Fisher Scientific, a U.S-based supplier of scientific instrumentation, reagents and consumables, and software services, announced that U.S. FDA had granted premarket approval to Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT targeted therapy.\n<\/p>\n

\nKey features of the study:<\/strong>\n<\/p>\n